{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:31:21Z","timestamp":1793431881037,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004263","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio Grande do Sul","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004263","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["21\/2551-0000104-6"],"award-info":[{"award-number":["21\/2551-0000104-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jpba.2022.115108","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T12:50:32Z","timestamp":1666097432000},"page":"115108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia"],"prefix":"10.1016","volume":"222","author":[{"given":"Maria Eduarda","family":"Kr\u00fctzmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranieri Reichel","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"de Souza Guterres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Kohlrausch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine Comparsi","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Su\u00f1e","family":"Mattevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayde Seadi","family":"Torriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Maria","family":"Fogliatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Venzon","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2022.115108_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jpba.2022.115108_bib2","unstructured":"Novartis pharma produktions GMBH, WEHR, Alemanha. Gilvec\u00ae. Imatinibe. VPS23: Glivec Bula Profissional, (2019)."},{"key":"10.1016\/j.jpba.2022.115108_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles","volume":"50","author":"Di Gion","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2022.115108_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2012.066480","article-title":"Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy","volume":"98","author":"Angelini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jpba.2022.115108_bib5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1476-5381.2010.00946.x","article-title":"Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes","volume":"161","author":"Nebot","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jpba.2022.115108_bib6","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1158\/1078-0432.CCR-05-2596","article-title":"Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors","volume":"12","author":"Delbaldo","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2022.115108_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2022.115108_bib8","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/bcp.13327","article-title":"Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib","volume":"83","author":"Lankheet","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2022.115108_bib9","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.4155\/bio.15.101","article-title":"DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application","volume":"7","author":"Antunes","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2022.115108_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106734","article-title":"No margin for non-adherence: probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study)","volume":"111","author":"Obeng-Kusi","year":"2021","journal-title":"Leuk. Res."},{"key":"10.1016\/j.jpba.2022.115108_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5581\/1516-8484.20130030","article-title":"Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance","volume":"35","author":"Rezende","year":"2013","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"10.1016\/j.jpba.2022.115108_bib12","first-page":"1213","article-title":"Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib. European","volume":"76","author":"Boons","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2022.115108_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114418","article-title":"Volumetric absorptive microsampling as a suitable tool to monitor tyrosine kinase inhibitors","volume":"207","author":"Verougstraete","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.115108_bib14","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation, EMA ICH draft, (2019). \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-ich-guideline-m10-bioanalytical-method-validation-step-2b_en.pdf\u3009."},{"key":"10.1016\/j.jpba.2022.115108_bib15","unstructured":"U.S. Bioanalytical Method Validation Guidance for Industry, Department of Health and Human Services Food and Drug Administration, 2018, pp. 1\u201341."},{"key":"10.1016\/j.jpba.2022.115108_bib16","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.clinbiochem.2016.05.004","article-title":"Dried blood spots analysis with mass spectrometry: potentials and pitfalls in therapeutic drug monitoring","volume":"49","author":"Antunes","year":"2016","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jpba.2022.115108_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med. Care"},{"key":"10.1016\/j.jpba.2022.115108_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jpba.2018.04.001","article-title":"Extractability-mediated stability bias and hematocrit impact: high extraction recovery is critical to feasibility of volumetric adsorptive microsampling (VAMS) in regulated bioanalysis","volume":"15","author":"Xie","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.115108_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225225","article-title":"Development and validation of LC-MS\/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients","volume":"14","author":"Iacuzzi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2022.115108_bib20","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/pharmaceutics14061216","article-title":"Relevance of therapeutic drug monitoring of tyrosine kinase inhibitors in routine clinical practice: a pilot study","volume":"14","author":"Escudero-Ortiz","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpba.2022.115108_bib21","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.4155\/bio.13.156","article-title":"Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions","volume":"16","author":"De Kesel","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2022.115108_bib22","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.4155\/bio.11.132","article-title":"EBF recommendation on the validation of bioanalytical methods for dried blood spots","volume":"3","author":"Timmerman","year":"2011","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2022.115108_bib23","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1182\/blood.V112.11.4286.4286","article-title":"South Brazilian Chronic Myeloid Leukemia (CML) profile patients: how we treat and our results","volume":"112","author":"Fogliatto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2022.115108_bib24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/clpt.2010.186","article-title":"Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia","volume":"88","author":"Takahashi","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2022.115108_bib25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jpba.2022.115108_bib26","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"IRIS (International Randomized Interferon vs STI571) Study Group. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2022.115108_bib27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1570-0232(02)00244-1","article-title":"Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods","volume":"774","author":"Almeida","year":"2002","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522005295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522005295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:25:52Z","timestamp":1760001952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522005295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":27,"alternative-id":["S0731708522005295"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115108","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115108"}}